{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-045724","form_type":"8-K","ticker":"VNDA","cik":"0001347178","company_name":"Vanda Pharmaceuticals Inc.","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.230070+00:00","generated_at":"2026-05-30T04:24:00.734660+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vanda Q3 2024 revenue up 23% to $47.7M; guidance raised; net loss $5.3M","bullets":["Q3 total net product sales $47.7M (+23% YoY); Fanapt $23.9M (+12%), HETLIOZ $17.9M (+2%), PONVORY $5.9M (-32% QoQ).","Net loss $5.3M vs net income $0.1M in Q3 2023; diluted EPS loss $0.09.","Cash $376.3M; guidance raised: FY revenue $190-210M, year-end cash $370-390M.","Fanapt bipolar I launch: new patient starts +90% Q3 2024 vs Q3 2023; Fanapt LAI Phase III starts Q4 2024.","Milsaperidone NDA for schizophrenia/bipolar I expected early 2025; tradipitant NDA for motion sickness in Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-045724","json":"https://secwatch.observer/filing/0001628280-24-045724.json","markdown":"https://secwatch.observer/filing/0001628280-24-045724.md","text":"https://secwatch.observer/filing/0001628280-24-045724.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347178/000162828024045724/0001628280-24-045724-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347178/000162828024045724/vnda-20241106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:24:00.734660+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}